Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-06-09
2009-06-09
Carlson, Karen Cochrane (Department: 1656)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S300000
Reexamination Certificate
active
07544654
ABSTRACT:
A method of reducing damage to cells and tissue caused by an ischemic or hypoxic event is disclosed. The method includes administering to the cell or tissue, either in vivo or ex vivo, ψεRACK peptide. The peptide can be administered before, during or after the ischemic or hypoxic event.
REFERENCES:
patent: 5783405 (1998-07-01), Mochly-Rosen et al.
patent: 6165977 (2000-12-01), Mochly-Rosen
patent: 6329349 (2001-12-01), Liang et al.
patent: 6855693 (2005-02-01), Mochly-Rosen et al.
patent: WO 98/17299 (1998-04-01), None
patent: WO 99/46403 (1999-09-01), None
patent: WO 00/47765 (2000-08-01), None
Schwarze et al. 1999; In vivo protein transduction: Delivery of biologically active protein into the mouse. Science 285: 1569-1572.
Rothbard et al. Nov. 2000; Conjugation of arginine oligomers to cyclosporine A facilitates topical delivery and inhibition of inflammation. Nature Medicine. 6(11): 1253-1257.
Chen et al.,Chemistry&Biology, 8:1123-1129 (2001).
Dorn et al.,PNAS, 96(22):12798-12803 (1999).
Hahn et al.,Circulation, 102(18): Abstract No. 770 (2000).
Ron and Mochly-Rosen,PNAS, 92:492-496 (1995).
Aley et al., “Chronic hypersensitivity for inflammatory nociceptor sensitization mediated by the epsilon isozyme of protein kinase C.”The Journal of Neuroscience, 20(12): 4680-5 (2000).
Brzoska et al., “The product of the ataxia-telangiectasia group D complementing gene, ATDC, interacts with a protein kinase C substrate and inhibitor,”Proc Natl Acad Sci U S A, 2(17):7824-8 (1995).
Cardone et al., “Phorbol myristate acetate-mediated stimulation of transcytosis and apical recycling in MDCK cells.”The Journal of Cell Biology, 124(5): 717-27 (1994).
Cardone et al., “Signal transduction by the polymoric immunoglobulin receptor suggests a role in regulation of receptor transcytosis.”The Journal of Cell Biology, 133(5):997-1005 (1996).
Chen et al., “Cardioprotection from ischemia by a brief exposure to physiological levels of ethanol: role of epsilon protein kinase C.”Proc Natl Acad Sci U S A, 96(22):12784-9 (1999).
Csukai M. and Mochly-Rosen, D., “Molecular genetic approaches. II. Expression-interaction cloning.”,Methods in Molecular Biology, 88:133-9 (1998).
Csukai M. and Mochly-Rosen, D., “Pharmacologic modulation of protein kinase C isozymes: the role of RACKs and subcellular localisation.”,Pharmacological Research, 39(4):253-9 (1999).
Csukai et al., “The coatomer protein beta'-COP, a selective binding protein (RACK) for protein kinase Cepsilon.”,The Journal of Biological Chemistry, 272(46):29200-6 (1997).
Dempsey et al., “Protein kinase C isozymes and the regulation of diverse cell responses.”,Am J Physiol Lung Cell Mol Physiol., 279(3):L429-38 (2000).
Diamond et al., “The role of adenosine and adenosine transport in ethanol-induced cellular tolerance and dependence. Possible biologic and genetic markers of alcoholism.”,Annals N Y Academy of Sciences, 625:473-87 (1991).
Disatnik et al., “Distinct responses of protein kinase C isozymes to c-erbB-2 activation in SKBR-3 human breast carcinoma cells.”,Cell Growth&Differentiation, 5(8):873-80 (1994).
Disatnik et al., “Localization of protein kinase C isozymes in cardiac myocytes.”,Experimental Cell Research, 210(2):287-97 (1994).
Disatnik et al., “Phospholipase C-gamma 1 binding to intracellular receptors for activated protein kinase C.”,Proc Natl Acad Sci U S A, 91(2):559-63 (1994).
Disatnik et al., “Stimulus-dependent subcellular localization of activated protein kinase C; a study with acidic fibroblast growth factor and transforming growth factor-beta 1 in cardiac myocytes.”,J Mol Cell Cardiol, 27(11):2473-81 (1995).
Dorn et al., “Sustained in vivo cardiac protection by a rationally designed peptide that causes epsilon protein kinase C translocation.”Proc Natl Acad Sci U S A, 96(22):12798-803 (1999).
Efendiev et al., “PKC-βand PKC-∫ mediate opposing effects on proximal tubule Na+, K+-ATPase activity”,FEBS Letters, 456:45-48 (1999).
Garcia-Navarro et al., “Developmental expression of protein kinase C subspecies in rat brain-pituitary axis.”,Molecular and Cellular Endocrinology, 103(1-2):133-8 (1994).
Gray et al., “A selective epsilon-protein kinase C antagonist inhibits protection of cardiac myocytes from hypoxia-induced cell death.”The Journal of Biological Chemistry, 272(49):30945-51 (1997).
Hu et al., “Evidence for functional role of epsilonPKC isozyme in the regulation of cardiac Ca(2+) channels.”,Am J Physiol Heart Circ Physiol., 279(6):H2658-64 (2000).
Hundle et al., “An inhibitory fragment derived from protein kinase Cepsilon prevents enhancement of nerve growth factor responses by ethanol and phorbol esters.”,The Journal of Biological Chemistry, 272(23):15028-35 (1997).
Johnson, J. A. and Mochly-Rosen, D., “Inhibition of the spontaneous rate of contraction of neonatal cardiac myocytes by protein kinase C isozymes. A putative role for the epsilon isozyme.”,Circ Res., 76(4):654-63 (1995).
Johnson et al., “A protein kinase C translocation inhibitor as an isozyme-selective antagonist of cardiac function.”The Journal of Biological Chemistry, 271(40):24962-6 (1996).
Johnson et al., “An improved permeabilization protocol for the introduction of peptides into cardiac myocytes. Application to protein kinase C research.”Circ Res., 79(6):1086-99 (1996).
Johnson et al., “Prolonged phorbol ester treatment down-regulates protein kinase C isozymes and increases contraction rate in neonatal cardiac myocytes.”,Life Sciences., 57(11):1027-38 (1995).
Knauf et al., “Involvement of protein kinase Cepsilon (PKCepsilon) in thyroid cell death. A truncated chimeric PKCepsilon cloned from a thyroid cancer cell line protects thyroid cells from apoptosis.”,The Journal of Biological Chemistry, 274(33):23414-25 (1999).
Laudanna et al., “Evidence of zeta protein kinase C involvement in polymorphonuclear neutrophil integrin-dependent adhesion and chemotaxis.”The Journal of Biological Chemistry, 273(46):30306-15 (1998).
Liu et al., “Protein kinase C-epsilon is responsible for the protection of preconditioning in rabbit cardiomyocytes.”,J Mol Cell Cardiol., 31(10):1937-48 (1999).
Mackay, K. and Mochly-Rosen, D., “An inhibitor of p38 mitogen-activated protein kinase protects neonatal cardiac myocytes from ischemia.”The Journal of Biological Chemistry, 274(10):6272-9 (1999).
Mackay, K. and Mochly-Rosen, D., “Involvement of a p38 mitogen-activated protein kinase phosphatase in protecting neonatal rat cardiac myocytes from ischemia.”,J Mol Cell Cardiol., 32(8):1585-8 (2000).
Miyamae et al., “Activation of epsilon protein kinase C correlates with a cardioprotective effect of regular ethanol consumption.”,Proc Natl Acad Sci U S A, 95(14):8262-7 (1998).
Mochly-Rosen, D., “Localization of protein kinases by anchoring proteins: a theme in signal transduction.”,Science, 268(5208):247-51 (1995).
Mochly-Rosen, D. and Gordon, A.S., “Anchoring proteins for protein kinase C: a means for isozyme selectivity.”,Faseb Journal, 12(1)35-42 (1998).
Mochly-Rosen, D. and Kauvar, L.M., “Modulating protein kinase C signal transduction.”,Advances in Pharmacology., 44:91-145 (1998).
Mochly-Rosen, D. and Kauvar, L.M., “Pharmacological regulation of network kinetics by protein kinase C localization.”,Seminars in Immunology, 12(1):55-61 (2000).
Mochly-Rosen et al., “Interaction of protein kinase C with RACK1, a receptor for activated C-kinase: a role in beta protein kinase C mediated signal transduction.”,Biochemistry Society Transactions, 23(3):596-600 (1995).
Mochly-Rosen et al., “A protein kinase C isozyme is translocated to cytoskeletal elements on activation.”,Cel
Carlson Karen Cochrane
King & Spalding LLP
Mohr Judy M.
The Board of Trustees of the Leland Stanford Junior University
LandOfFree
ψεRACK peptide composition and method for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with ψεRACK peptide composition and method for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and ψεRACK peptide composition and method for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4148421